EGFR and non-small cell lung carcinoma: In NSCLC, the short deletions in exon 19 and the G719S, L858R, and L861Q point mutation in exon 21 account for around 90% of all EGFR gene mutations, and therefore they predict better responsiveness to anti-EGFR therapy [58,59,60].